ATE525397T1 - Antikörpermoleküle mit spezifität für humanes il- 1 beta - Google Patents
Antikörpermoleküle mit spezifität für humanes il- 1 betaInfo
- Publication number
- ATE525397T1 ATE525397T1 AT04708808T AT04708808T ATE525397T1 AT E525397 T1 ATE525397 T1 AT E525397T1 AT 04708808 T AT04708808 T AT 04708808T AT 04708808 T AT04708808 T AT 04708808T AT E525397 T1 ATE525397 T1 AT E525397T1
- Authority
- AT
- Austria
- Prior art keywords
- specificity
- beta
- human
- antibody molecules
- antibody
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
- C07K16/245—IL-1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Transplantation (AREA)
- Vascular Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Psychiatry (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0303337.0A GB0303337D0 (en) | 2003-02-13 | 2003-02-13 | Biological products |
PCT/GB2004/000463 WO2004072116A2 (en) | 2003-02-13 | 2004-02-06 | ANTIBODY MOLECULES HAVING SPECIFICITY FOR HUMAN IL-1β |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE525397T1 true ATE525397T1 (de) | 2011-10-15 |
Family
ID=9952969
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT04708808T ATE525397T1 (de) | 2003-02-13 | 2004-02-06 | Antikörpermoleküle mit spezifität für humanes il- 1 beta |
Country Status (26)
Country | Link |
---|---|
US (2) | US7608694B2 (de) |
EP (2) | EP1597282B1 (de) |
JP (2) | JP4668896B2 (de) |
KR (1) | KR20050099509A (de) |
CN (1) | CN1745103A (de) |
AR (1) | AR043159A1 (de) |
AT (1) | ATE525397T1 (de) |
AU (1) | AU2004210776B2 (de) |
BR (1) | BRPI0407233A (de) |
CA (1) | CA2515474C (de) |
CL (1) | CL2004000259A1 (de) |
CY (1) | CY1112507T1 (de) |
DK (1) | DK1597282T3 (de) |
EA (1) | EA200501286A1 (de) |
EC (1) | ECSP056014A (de) |
ES (1) | ES2373953T3 (de) |
GB (1) | GB0303337D0 (de) |
IS (1) | IS8013A (de) |
MX (1) | MXPA05007392A (de) |
NO (1) | NO20054223L (de) |
PE (1) | PE20040947A1 (de) |
PL (1) | PL378412A1 (de) |
PT (1) | PT1597282E (de) |
SI (1) | SI1597282T1 (de) |
TW (1) | TW200505942A (de) |
WO (1) | WO2004072116A2 (de) |
Families Citing this family (53)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0303337D0 (en) | 2003-02-13 | 2003-03-19 | Celltech R&D Ltd | Biological products |
GEP20105059B (en) | 2004-07-26 | 2010-08-10 | Biogen Idec Inc | Anti-cd154 antibodies |
CA2590164A1 (en) | 2005-01-26 | 2006-08-03 | Amgen Fremont Inc. | Antibodies against interleukin-1 beta |
ATE446972T1 (de) | 2005-06-21 | 2009-11-15 | Xoma Technology Ltd | Il-1 bindende antikörper und fragmente davon |
GB0513852D0 (en) * | 2005-07-06 | 2005-08-10 | Celltech R&D Ltd | Biological products |
CN102861332A (zh) * | 2005-10-26 | 2013-01-09 | 诺瓦提斯公司 | IL-1β化合物的新用途 |
PL1960430T3 (pl) | 2005-12-09 | 2015-03-31 | Ucb Pharma Sa | Cząsteczki przeciwciał wykazujące swoistość dla ludzkiej il-6 |
GB0612928D0 (en) * | 2006-06-29 | 2006-08-09 | Ucb Sa | Biological products |
GB0620729D0 (en) | 2006-10-18 | 2006-11-29 | Ucb Sa | Biological products |
CA2673592C (en) | 2006-12-20 | 2014-03-25 | Xoma Technology Ltd. | Methods for the treatment of il-1.beta. related diseases |
EP3524626A1 (de) | 2007-03-22 | 2019-08-14 | Biogen MA Inc. | Bindungsproteine, mit antikörpern, antikörperderivaten und antikörperfragmenten, mit spezifischer bindung an cd154 sowie verwendungen davon |
GB0717337D0 (en) | 2007-09-06 | 2007-10-17 | Ucb Pharma Sa | Method of treatment |
RS56930B1 (sr) | 2007-12-07 | 2018-05-31 | Zymogenetics Inc | Molekuli humanizovanih antitela specifični za il-31 |
ES2527326T3 (es) | 2007-12-20 | 2015-01-22 | Xoma (Us) Llc | Métodos para el tratamiento de la gota |
GB0807413D0 (en) | 2008-04-23 | 2008-05-28 | Ucb Pharma Sa | Biological products |
MX2010011761A (es) * | 2008-04-28 | 2010-11-30 | Kalobios Pharmaceuticals Inc | Anticuerpos para el factor que estimula la colonia del granulocito-macrofago. |
JP2012502059A (ja) | 2008-09-05 | 2012-01-26 | ゾーマ テクノロジー リミテッド | IL−1β関連疾患を処置または予防するための方法 |
MY157473A (en) | 2009-02-17 | 2016-06-15 | Ucb Biopharma Sprl | Antibody molecules having specificity for human ox40 |
GB0904214D0 (en) | 2009-03-11 | 2009-04-22 | Ucb Pharma Sa | Biological products |
ES2692811T3 (es) | 2009-09-24 | 2018-12-05 | Ucb Biopharma Sprl | Cepa bacteriana para expresión de proteína recombinante que tiene los genes DEGP deficiente de proteasa que retiene actividad chaperona y TSP y PTR desactivados génicamente |
BR112012007365A2 (pt) * | 2009-10-15 | 2016-11-22 | Abbott Lab | proteínas de ligação à il-1 |
GB201000590D0 (en) | 2010-01-14 | 2010-03-03 | Ucb Pharma Sa | Bacterial host strain |
GB201000591D0 (en) | 2010-01-14 | 2010-03-03 | Ucb Pharma Sa | Bacterial hoist strain |
GB201000587D0 (en) | 2010-01-14 | 2010-03-03 | Ucb Pharma Sa | Bacterial hoist strain |
BR112012028557A2 (pt) | 2010-05-07 | 2019-09-24 | Xoma Technology Ltd. | uso de um anticorpo anti-il-1b ou de fragmentos de ligação do mesmo. |
AR081246A1 (es) | 2010-05-14 | 2012-07-18 | Abbott Lab | Proteinas de union a il-1 |
GB201012599D0 (en) | 2010-07-27 | 2010-09-08 | Ucb Pharma Sa | Process for purifying proteins |
US8465413B2 (en) | 2010-11-25 | 2013-06-18 | Coloplast A/S | Method of treating Peyronie's disease |
BR112013017951B1 (pt) | 2011-01-14 | 2022-09-27 | UCB Biopharma SRL | Anticorpo de neutralização, sequência de dna isolada, vetor de clonagem ou expressão, processo para a produção do anticorpo, composição farmacêutica, uso de anticorpo e uso da composição farmacêutica |
US9725516B2 (en) | 2011-07-13 | 2017-08-08 | Ucb Pharma, S.A. | Bacterial host strain expressing recombinant DSBC |
UA112203C2 (uk) | 2011-11-11 | 2016-08-10 | Юсб Фарма С.А. | Злитий білок біоспецифічного антитіла, який зв'язується з ox40 людини та сироватковим альбуміном людини |
US20150017157A1 (en) | 2011-12-19 | 2015-01-15 | Xoma (Us) Llc | Methods for treating acne |
JP6383665B2 (ja) | 2012-02-13 | 2018-08-29 | エージェンシー フォー サイエンス,テクノロジー アンド リサーチ | IL‐1β中和ヒトモノクローナル抗体 |
WO2013157105A1 (ja) * | 2012-04-18 | 2013-10-24 | 公立大学法人大阪市立大学 | ムチンサブタイプ5ac特異的ヒト化抗体およびその利用 |
WO2013157102A1 (ja) * | 2012-04-18 | 2013-10-24 | 公立大学法人大阪市立大学 | ムチンサブタイプ5ac特異的ヒト化抗体およびその利用 |
GB201208367D0 (en) | 2012-05-14 | 2012-06-27 | Ucb Pharma Sa | Biological product |
WO2014011955A2 (en) | 2012-07-12 | 2014-01-16 | Abbvie, Inc. | Il-1 binding proteins |
CN104341501B (zh) * | 2013-07-29 | 2019-08-30 | 上海睿智化学研究有限公司 | 抗IL-1β人源化单克隆抗体及其制备方法和应用 |
ES2916825T3 (es) | 2014-01-20 | 2022-07-06 | UCB Biopharma SRL | Procedimiento para la reconstitución de una forma sólida de una composición farmacéutica |
GB201501613D0 (en) | 2015-01-30 | 2015-03-18 | Ucb Biopharma Sprl | Treatment of autoimmune disorders with CD154 antibodies |
US9560393B2 (en) * | 2015-02-20 | 2017-01-31 | Disney Enterprises, Inc. | Media processing node |
CN106349388B (zh) * | 2015-07-17 | 2021-04-02 | 上海佳文英莉生物技术有限公司 | 一种促细胞程序性坏死抗体及其应用 |
WO2017072183A1 (en) | 2015-10-27 | 2017-05-04 | Ucb Biopharma Sprl | Methods of treatment using anti-il-17a/f antibodies |
GB201616596D0 (en) | 2016-09-29 | 2016-11-16 | Nascient Limited | Epitope and antibodies |
CN110818793A (zh) * | 2018-08-14 | 2020-02-21 | 中山康方生物医药有限公司 | 抗IL-1β的抗体、其药物组合物及其用途 |
CN113383016B (zh) * | 2018-11-07 | 2022-09-13 | 三生国健药业(上海)股份有限公司 | 结合人IL-1β的抗体、其制备方法和用途 |
GB201919062D0 (en) | 2019-12-20 | 2020-02-05 | Ucb Biopharma Sprl | Antibody |
IL303294A (en) | 2020-12-07 | 2023-07-01 | UCB Biopharma SRL | Antibodies against interleukin-22 |
CN116670166A (zh) | 2020-12-07 | 2023-08-29 | Ucb生物制药有限责任公司 | 多特异性抗体和抗体组合 |
WO2022233764A1 (en) | 2021-05-03 | 2022-11-10 | UCB Biopharma SRL | Antibodies |
GB202111905D0 (en) | 2021-08-19 | 2021-10-06 | UCB Biopharma SRL | Antibodies |
CN113855807A (zh) * | 2021-10-25 | 2021-12-31 | 孙良丹 | 一种试剂在制备治疗/抑制银屑病药物中的应用 |
CN114524875B (zh) * | 2021-11-11 | 2023-07-25 | 江苏莱森生物科技研究院有限公司 | 偶联IL-1β单克隆抗体的纳米硅球及应用 |
Family Cites Families (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB129105A (en) | 1918-07-02 | 1919-07-02 | Alfred George Hubble | Improvements in and connected with Closing Means for Milk Churns, Containers and Vessels. |
EP0569687B1 (de) | 1984-05-18 | 2002-08-21 | New England Medical Center Hospitals, Inc. | Menschliche IL-1 cDNS-Sequenzen die für biologisch aktive menschliche IL-1-Proteine kodieren |
GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
DK336987D0 (da) | 1987-07-01 | 1987-07-01 | Novo Industri As | Immobiliseringsmetode |
US4935343A (en) | 1986-08-08 | 1990-06-19 | Syntex (U.S.A.) Inc. | Monoclonal antibodies for interleukin-1β |
US5474899A (en) * | 1987-05-13 | 1995-12-12 | Cistron Biotechnology, Inc. | Selective immunoassay for IL-1 β |
GB8719042D0 (en) | 1987-08-12 | 1987-09-16 | Parker D | Conjugate compounds |
GB8907617D0 (en) | 1989-04-05 | 1989-05-17 | Celltech Ltd | Drug delivery system |
GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
GB9112536D0 (en) | 1991-06-11 | 1991-07-31 | Celltech Ltd | Chemical compounds |
GB9120467D0 (en) | 1991-09-26 | 1991-11-06 | Celltech Ltd | Anti-hmfg antibodies and process for their production |
WO1995001997A1 (en) | 1993-07-09 | 1995-01-19 | Smithkline Beecham Corporation | RECOMBINANT AND HUMANIZED IL-1β ANTIBODIES FOR TREATMENT OF IL-1 MEDIATED INFLAMMATORY DISORDERS IN MAN |
JP4231106B2 (ja) | 1995-01-23 | 2009-02-25 | ゼノテック インコーポレイティッド | 骨溶解および転移を改善する方法 |
JPH09183799A (ja) * | 1995-11-06 | 1997-07-15 | Merck Patent Gmbh | ヒト化モノクローナル抗体 |
US5980898A (en) | 1996-11-14 | 1999-11-09 | The United States Of America As Represented By The U.S. Army Medical Research & Material Command | Adjuvant for transcutaneous immunization |
GB9625640D0 (en) | 1996-12-10 | 1997-01-29 | Celltech Therapeutics Ltd | Biological products |
GB9720054D0 (en) * | 1997-09-19 | 1997-11-19 | Celltech Therapeutics Ltd | Biological products |
GB0001448D0 (en) | 2000-01-21 | 2000-03-08 | Novartis Ag | Organic compounds |
GB0013810D0 (en) * | 2000-06-06 | 2000-07-26 | Celltech Chiroscience Ltd | Biological products |
GB0020685D0 (en) | 2000-08-22 | 2000-10-11 | Novartis Ag | Organic compounds |
US20030026806A1 (en) * | 2000-10-27 | 2003-02-06 | Amgen Inc. | Antibodies and other selective IL-1 binding agents that allow binding to IL-1 receptor but not activation thereof |
AU2002355249A1 (en) * | 2001-07-26 | 2003-02-17 | Eli Lilly And Company | Interleukin-1 beta antibodies |
GB0303337D0 (en) | 2003-02-13 | 2003-03-19 | Celltech R&D Ltd | Biological products |
-
2003
- 2003-02-13 GB GBGB0303337.0A patent/GB0303337D0/en not_active Ceased
-
2004
- 2004-02-06 SI SI200431797T patent/SI1597282T1/sl unknown
- 2004-02-06 DK DK04708808.3T patent/DK1597282T3/da active
- 2004-02-06 BR BR0407233-2A patent/BRPI0407233A/pt not_active Application Discontinuation
- 2004-02-06 KR KR1020057013813A patent/KR20050099509A/ko not_active Application Discontinuation
- 2004-02-06 US US10/544,911 patent/US7608694B2/en not_active Expired - Fee Related
- 2004-02-06 EA EA200501286A patent/EA200501286A1/ru unknown
- 2004-02-06 WO PCT/GB2004/000463 patent/WO2004072116A2/en active Application Filing
- 2004-02-06 PL PL378412A patent/PL378412A1/pl unknown
- 2004-02-06 MX MXPA05007392A patent/MXPA05007392A/es not_active Application Discontinuation
- 2004-02-06 AU AU2004210776A patent/AU2004210776B2/en not_active Ceased
- 2004-02-06 PT PT04708808T patent/PT1597282E/pt unknown
- 2004-02-06 CN CNA2004800033654A patent/CN1745103A/zh active Pending
- 2004-02-06 AT AT04708808T patent/ATE525397T1/de active
- 2004-02-06 EP EP04708808A patent/EP1597282B1/de not_active Expired - Lifetime
- 2004-02-06 EP EP10182246A patent/EP2287193A1/de not_active Withdrawn
- 2004-02-06 CA CA2515474A patent/CA2515474C/en not_active Expired - Fee Related
- 2004-02-06 JP JP2006502246A patent/JP4668896B2/ja not_active Expired - Fee Related
- 2004-02-06 ES ES04708808T patent/ES2373953T3/es not_active Expired - Lifetime
- 2004-02-09 PE PE2004000142A patent/PE20040947A1/es not_active Application Discontinuation
- 2004-02-12 TW TW093103340A patent/TW200505942A/zh unknown
- 2004-02-12 CL CL200400259A patent/CL2004000259A1/es unknown
- 2004-02-12 AR ARP040100431A patent/AR043159A1/es unknown
-
2005
- 2005-09-07 IS IS8013A patent/IS8013A/is unknown
- 2005-09-12 NO NO20054223A patent/NO20054223L/no unknown
- 2005-09-13 EC EC2005006014A patent/ECSP056014A/es unknown
-
2009
- 2009-09-29 US US12/569,700 patent/US8465744B2/en not_active Expired - Fee Related
-
2010
- 2010-06-04 JP JP2010128372A patent/JP2010246553A/ja active Pending
-
2011
- 2011-12-21 CY CY20111101274T patent/CY1112507T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE525397T1 (de) | Antikörpermoleküle mit spezifität für humanes il- 1 beta | |
CY2018027I2 (el) | Ανταγωνιστικα αντισωματα il-17 | |
IL242434B (en) | Antibody molecules with selectivity for 6-il of human origin | |
LTC2848258I2 (lt) | Šeiminės Viduržemio jūros karštligės gydymas su anti-IL-1 beta antikūnais | |
LTPA2016026I1 (lt) | Anti-il-17 antikūnai | |
DK1599504T3 (da) | Modificeret antistof | |
DK1976877T3 (da) | Monoklonale antistoffer mod amyloid-beta-protein og anvendelser heraf | |
DE602005015238D1 (de) | Prothese für Annuloplastie mit auxetischer Struktur | |
DK1691837T3 (da) | IP-10-antistoffer og anvendelse heraf | |
DE602004007503D1 (de) | REKONFIGURIERBARE ARCHITEKTUR FÜR SOCs | |
DE602004026768D1 (de) | Therapeutische anti-igfr1-antikörper-kombinationen | |
DE60312777D1 (de) | Inkubator für Neugeborene | |
NO20071430L (no) | Anti-OX4OL antistoffer | |
NO20076607L (no) | TWEAK - bindende antistoff | |
DK1964852T3 (da) | Anti-ilt7-antistof | |
DK1853310T3 (da) | Anti-Abeta-antistofpræparat | |
ATE424904T1 (de) | Bausatz für komplexe konstruktionen | |
DE602005005920D1 (de) | Befestigungsvorrichtung für Rollstuhl | |
DE602004000756D1 (de) | Doppelköderstation für insekten | |
BRPI0509495A2 (pt) | anticorpo humanizado | |
DE602004000699D1 (de) | Spielausgleichelement für Ventiltrieb | |
DE60324848D1 (de) | Ausgleichsmechanismus für drehwelle | |
DE50208368D1 (de) | Rinnenschuss für strebförderer mit laderampe | |
DE502004008685D1 (de) | Fadenführervorrichtung für ringspindel | |
DE502004005355D1 (de) | Dosierventil mit Längenkompensationseinheit |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
UEP | Publication of translation of european patent specification |
Ref document number: 1597282 Country of ref document: EP |